Pattern recognition
From the latest edition of each brief.
Biotech & Pharma Intelligence
Pan-RAS drugs move toward first line. Revolution’s chemotherapy combination and Erasca’s monotherapy both report pancreatic cancer responses this week, and both companies point to first-line Phase 3 trials. Neither result is randomized. Analysis
Tuberculosis regimens. NEJM’s PARADIGM4TB and BioVersys’s ENABLE both test new drug combinations against standard treatment; only the NEJM trial gives numbers. Analysis
Complement in myasthenia gravis. Livsayis follows Klygefa, which FDA lists as approved for the disease on 11.13; two approvals in a week give patients more dosing choices, not a new mechanism. Analysis
AI & Technology Intelligence
On 11.05 and again this week, the stocks that fell most were chips, memory and the neoclouds, while the cloud buyers fell less. The selling follows the supply chain outward from the companies that write the checks. Analysis

